248 related articles for article (PubMed ID: 8285019)
1. Subcutaneous recombinant human erythropoietin for the treatment of anemia in myelodysplastic syndromes.
Ghio R; Balleari E; Ballestrero A; Gatti AM; Mareni C; Massa G; Patrone F; Sessarego M; Timitilli S
Acta Haematol; 1993; 90(2):58-64. PubMed ID: 8285019
[TBL] [Abstract][Full Text] [Related]
2. Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes.
Balleari E; Clavio M; Arboscello E; Bellodi A; Bruzzone A; Del Corso L; Lucchetti MV; Miglino M; Passalia C; Pierri I; Ponassi I; Oneto C; Racchi O; Scudeletti M; Vignolo L; Zoppoli G; Gobbi M; Ghio R
Leuk Res; 2011 Nov; 35(11):1472-6. PubMed ID: 21794914
[TBL] [Abstract][Full Text] [Related]
3. In vitro studies of erythropoietin-dependent regulation of erythropoiesis in myelodysplastic syndromes.
Merchav S; Nielsen OJ; Rosenbaum H; Sharon R; Brenner B; Tatarsky I; Scigalla P; Wieczorek L
Leukemia; 1990 Nov; 4(11):771-4. PubMed ID: 2232891
[TBL] [Abstract][Full Text] [Related]
4. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
[TBL] [Abstract][Full Text] [Related]
5. Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis.
Balleari E; Filiberti RA; Salvetti C; Allione B; Angelucci E; Bruzzone M; Calzamiglia T; Cavaliere M; Cavalleri M; Cilloni D; Clavio M; Crisà E; Da Col A; Danise P; Pilo F; Ferrero D; Finelli C; Gioia D; Lemoli RM; Masiera E; Messa E; Miglino M; Musto P; Natalie Oliva E; Poloni A; Salvi F; Sanna A; Scudeletti M; Tassara R; Santini V
Cancer Med; 2019 Dec; 8(18):7567-7576. PubMed ID: 31657156
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of recombinant human erythropoietin in the treatment of refractory anemias without excess of blasts in myelodysplastic syndromes.
Isnard F; Najman A; Jaar B; Fenaux P; Baillou C; Khoury E; Labopin M; Laporte JP; Woler M; Gorin NC
Leuk Lymphoma; 1994 Jan; 12(3-4):307-14. PubMed ID: 8167562
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin may improve anemia in selected patients with myelodysplastic syndromes.
Hansen PB; Johnsen HE; Hippe E; Hellström-Lindberg E; Ralfkiaer E
Am J Hematol; 1993 Dec; 44(4):229-36. PubMed ID: 8237992
[TBL] [Abstract][Full Text] [Related]
8. Serial changes in endogenous erythropoietin levels in patients with myelodysplastic syndromes and aplastic anemia undergoing erythropoietin treatment.
Yoshida Y; Anzai N; Kawabata H; Kohsaka Y; Okuma M
Ann Hematol; 1993 Apr; 66(4):175-80. PubMed ID: 8485205
[TBL] [Abstract][Full Text] [Related]
9. Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin.
Mantovani L; Lentini G; Hentschel B; Wickramanayake PD; Loeffler M; Diehl V; Tesch H
Br J Haematol; 2000 May; 109(2):367-75. PubMed ID: 10848827
[TBL] [Abstract][Full Text] [Related]
10. High-dose recombinant human erythropoietin for treatment of anemia in myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria: a pilot study.
Stebler C; Tichelli A; Dazzi H; Gratwohl A; Nissen C; Speck B
Exp Hematol; 1990 Dec; 18(11):1204-8. PubMed ID: 2226680
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human erythropoietin for treatment of myelodysplastic syndromes.
Rafanelli D; Grossi A; Longo G; Vannucchi AM; Bacci P; Ferrini PR
Leukemia; 1992 Apr; 6(4):323-7. PubMed ID: 1588794
[TBL] [Abstract][Full Text] [Related]
12. Current use of recombinant human erythropoietin (r-huEPO) in the management of symptomatic anaemia in patients with myelodysplastic syndromes (MDS).
Marques da Costa R
Sangre (Barc); 1994 Apr; 39(2):105-10. PubMed ID: 8059287
[TBL] [Abstract][Full Text] [Related]
13. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
14. Response to recombinant human erythropoietin in patients with myelodysplastic syndromes.
Stasi R; Brunetti M; Bussa S; Conforti M; Di Giulio C; Crescenzi A; Terzoli E; Vecchione A; Pagano A
Clin Cancer Res; 1997 May; 3(5):733-9. PubMed ID: 9815743
[TBL] [Abstract][Full Text] [Related]
15. Treatment of anemia in low risk myelodysplastic syndromes with granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin.
Economopoulos T; Mellou S; Papageorgiou E; Pappa V; Kokkinou V; Stathopoulou E; Pappa M; Raptis S
Leukemia; 1999 Jul; 13(7):1009-12. PubMed ID: 10400415
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial.
Cazzola M; Ponchio L; Beguin Y; Rosti V; Bergamaschi G; Liberato NL; Fregoni V; Nalli G; Barosi G; Ascari E
Blood; 1992 Jan; 79(1):29-37. PubMed ID: 1728318
[TBL] [Abstract][Full Text] [Related]
17. High doses of intravenous recombinant erythropoietin for the treatment of anaemia in myelodysplastic syndrome.
Goy A; Belanger C; Casadevall N; Picard F; Guesnu M; Jaulmes D; Poisson D; Varet B
Br J Haematol; 1993 Jun; 84(2):232-7. PubMed ID: 8398823
[TBL] [Abstract][Full Text] [Related]
18. Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes.
Stenke L; Wallvik J; Celsing F; Hast R
Leukemia; 1993 Sep; 7(9):1324-7. PubMed ID: 8371582
[TBL] [Abstract][Full Text] [Related]
19. In vitro study of erythropoiesis in patients with aplastic anemia and myelodysplastic syndromes: a possible tool for prospective determination of the clinical effectiveness of growth factors.
Aoki A; Shibata A
Hematol Pathol; 1992; 6(3):143-53. PubMed ID: 1429342
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: a clinical and erythrokinetic assessment.
Verhoef GE; Zachée P; Ferrant A; Demuynck H; Selleslag D; Van Hove L; Deckers F; Boogaerts MA
Ann Hematol; 1992 Jan; 64(1):16-21. PubMed ID: 1739754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
